No Data
No Data
Hainan Huluwa Pharmaceutical Group (605199.SH): The company's PE and PB ratios are much higher than the industry average, which may indicate irrational speculation.
Gelonghui reported on December 4th that Hainan Huluwa Pharmaceutical Group (605199.SH) announced that its stocks have been on a continuous涨停 for 7 trading days from November 26, 2024 to December 4, 2024, with a cumulative increase of 94.89%, and the turnover ratio for the last 7 trading days is 29.65%. The company's stock price rise is significantly higher than the average level of the sse composite index and the pharmaceutical manufacturing industry during the same period, which may indicate irrational speculation. The company specifically reminds investors that there has been no significant change in its fundamentals, and urges all investors to be aware of secondary market trading risks, make rational decisions, and invest prudently. As of December 3, 2024,
The hainan huluwa pharmaceutical group (605199.SH) has had a significant short-term increase in stock prices, which may be due to irrational speculation.
Hainan Huluwa Pharmaceutical Group (605199.SH) has issued a risk warning announcement stating that the company's stock price has increased significantly in the short term, which may pose...
Subdued Growth No Barrier To Hainan Huluwa Pharmaceutical Group Co., Ltd. (SHSE:605199) With Shares Advancing 43%
In November, the frenzy of "mystical stock trading" is in full swing, with the strongest bull stock experiencing 15 daily limit-ups in 20 days, trading Eastern related stocks, zodiac Snake related stocks, numerical series, etc...
Attention economy.
Hainan Huluwa Pharmaceutical Group (605199.SH): There are no significant matters that should have been disclosed but have not been disclosed.
On November 29, Glonghui reported that hainan huluwa pharmaceutical group (605199.SH) announced that its stocks have experienced a continuous daily price limit rise from November 26, 2024, to November 29, 2024, with a cumulative increase of 46.40%. The turnover ratio over the last four trading days has reached 19.83%. The company specifically reminds investors to be aware of risks in the secondary market, make rational decisions, and invest cautiously. After the company's self-inspection and written verification with its controlling shareholder and actual controller, it is confirmed that as of the date of this announcement, there are no significant matters that should be disclosed but have not been disclosed.
hainan huluwa pharmaceutical group (605199.SH): Zhongjia Rui has cumulatively reduced their shareholding by 1.33%.
Hainan Huluwa Pharmaceutical Group (605199.SH) announced on November 27th that on November 26, 2024, the company received a notice from Zhongjiarui regarding the completion of the implementation of the shareholding reduction plan. Zhongjiarui reduced a total of 5,341,050 shares between November 25, 2024 and November 26, 2024, accounting for 1.33% of the company's total share capital.
Hainan Huluwa Pharmaceutical Group Co., Ltd. (SHSE:605199) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely
No Data
